

## China-based I-Mab appoints new COO and CMO

29 April 2022 | News

### I-Mab announces appointments of Richard Yeh as Chief Operating Officer and John Hayslip as Chief Medical Officer



China's I-Mab, a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, announced the appointments of Richard Yeh as Chief Operating Officer and Dr John Hayslip as Chief Medical Officer.

Yeh will be based in Shanghai, China and report directly to Dr Jingwu Zang. He will join I-Mab's Board after the necessary process is completed. As the company upgrades its worldwide operations and strengthens network with international investors, Yeh will be leading key aspects of I-Mab's strategic investor interactions, global alliance management and major facilities across the world.

Yeh is an industry veteran with over 25 years of experience spanning senior leadership positions with biopharmaceutical companies and prominent Wall Street firms. Before joining I-Mab, Mr. Yeh was Chief Financial Officer and Head of Strategic Operations at Abbisko Therapeutics, overseeing financial transactions, strategic planning, financial & accounting reports, risk management and fundraising. He also held a series of leadership positions including Chief Financial Officer of CStone Pharmaceuticals, Managing Director and Business Unit Leader of Asia Pacific healthcare equity research at Goldman Sachs (Asia), and Head of China and regional healthcare research team at Citigroup Capital Markets Asia.

Dr Hayslip will be based in the United States and report directly to Dr. Andrew Zhu, President of I-Mab. In his new role, Dr. Hayslip will lead the Company's pipeline development, addressing the key challenges in clinical sciences to increase the probability of success and the speed of clinical development for I-Mab's innovative assets.

Before joining I-Mab, Dr Hayslip was Vice President of Clinical Development at Nektar Therapeutics. Dr Hayslip also led development activities for multiple therapies while at AbbVie Oncology. He also comes with a depth of experience on lemezoparlimab (TJC4), having assembled and led the AbbVie cross-functional team to complete setup for patient enrollment for the global partnership between I-Mab and AbbVie on lemezoparlimab. Prior to joining AbbVie Oncology, Dr Hayslip was an accomplished researcher and physician at the University of Kentucky's Markey Cancer Center, where he led numerous cancer research studies with a primary focus in lymphoma and leukemia. He also served as the Chief for Hematology and

Bone Marrow Transplant and as Director of Clinical Research and Data Management at the Markey Cancer Center.